A good test is whether a compromised device can reach patient records, directory services, or backup systems without an explicit, monitored control point. If the answer is yes, segmentation is only administrative on paper. Effective segmentation limits the blast radius of a device compromise and makes lateral movement visible.
Why This Matters for Security Teams
Medical device segmentation is not just a network design choice. It is a patient safety control, a resilience control, and often a compliance control at the same time. Security teams need to know whether segmentation actually limits what an infusion pump, imaging workstation, or connected monitor can reach if it is compromised. The practical question is whether the device can still communicate with systems that hold records, credentials, backups, or management tooling.
That matters because many environments rely on flat networks, permissive exception rules, or legacy vendor requirements that were approved once and then never re-tested. Current guidance from the NIST Cybersecurity Framework 2.0 emphasises risk-based control validation, which is exactly what segmentation testing should be. If the control cannot be demonstrated under failure conditions, it is not doing operational work. In practice, many security teams discover weak segmentation only after a maintenance account, remote support path, or outdated device image has already provided the route around it rather than through it.
How It Works in Practice
Effective testing starts with an asset and flow inventory. Security teams should identify which device classes exist, what they talk to, which ports and protocols are truly required, and which destinations are explicitly forbidden. That baseline should include clinical workflows, patching, logging, time sync, vendor support, and backup paths. A segment is working only if those permitted flows are narrow, documented, and observable.
Testing usually combines three methods: configuration review, validation of live traffic, and controlled attack simulation. Configuration review checks firewall rules, VLAN boundaries, host controls, and routing policies. Live traffic validation confirms that the device reaches only approved services and that blocked attempts are logged. Controlled simulation can be done with benign probes or red-team style exercises to see whether a compromised endpoint could pivot toward domain controllers, file shares, PACS, EHR systems, or backup repositories.
- Verify that only required destination IPs, ports, and service accounts are allowed.
- Confirm that denied connections generate alerts in SIEM or monitoring tools.
- Test whether management channels are separated from clinical data paths.
- Check that vendor remote access is time-bound, approved, and inspected.
- Retest after firmware updates, network changes, or new integrations.
Teams should also validate the “control point” itself. If a segment depends on a single firewall rule set but bypass paths exist through jump hosts, wireless overlays, or backup networks, the design is weaker than it appears. Mapping this work to CISA medical device security guidance helps anchor the review in operational reality. These controls tend to break down in hospitals with shared legacy networks and unmanaged third-party service paths because the exception process becomes more trusted than the segmentation policy.
Common Variations and Edge Cases
Tighter segmentation often increases operational overhead, requiring organisations to balance clinical uptime and vendor support against reduced attack surface. That tradeoff is especially visible in operating theatres, radiology, and life-support environments where devices may need limited connectivity for patient safety or manufacturer maintenance. Best practice is evolving here: there is no universal standard for how much access a device should have, only a requirement that every exception be justified, monitored, and periodically revalidated.
Some devices cannot support modern agents, certificates, or host-based controls, so enforcement must happen at the network layer. Others depend on broadcast discovery, shared update repositories, or legacy protocols that make coarse segmentation tempting but fragile. In those cases, teams should favour deny-by-default zoning, explicit allowlists, and strong inspection at the nearest feasible control point. The CISA medical device security resource and the FDA medical device cybersecurity guidance both reinforce the need to validate security claims against real device behaviour, not policy intent alone.
Where segmentation appears to work in the lab but fails in production, the usual cause is uncontrolled adjacency: shared admin domains, flat backup networks, or vendor tunnels that were never brought into the test plan. That is the edge case that matters most, because it turns “segmentation” into a diagram instead of a containment control.
Standards & Framework Alignment
This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.
MITRE ATT&CK address the attack and risk surface, while NIST CSF 2.0 and CIS Controls set the governance and control requirements practitioners need to meet.
| Framework | Control / Reference | Relevance |
|---|---|---|
| NIST CSF 2.0 | PR.AC-5 | Network access restrictions define whether device paths are truly segmented. |
| MITRE ATT&CK | T1021 | Lateral movement is the key behavior segmentation should prevent or expose. |
| CIS Controls | Control 12 | Network management controls support secure boundaries and traffic filtering. |
Restrict device communications to approved paths and verify enforcement after every change.
Related resources from NHI Mgmt Group
Deepen Your Knowledge
Reviewed and updated by the NHIMG editorial team on August 19, 2026.
NHI Mgmt Group — the #1 independent authority on Non-Human Identity, IAM, and Agentic AI security. nhimg.org
